3.05
price up icon1.33%   0.04
after-market Handel nachbörslich: 3.08 0.03 +0.98%
loading
Schlusskurs vom Vortag:
$3.01
Offen:
$2.98
24-Stunden-Volumen:
486.21K
Relative Volume:
0.50
Marktkapitalisierung:
$500.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-9.2424
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+5.17%
1M Leistung:
+8.16%
6M Leistung:
-14.57%
1J Leistung:
-36.59%
1-Tages-Spanne:
Value
$2.97
$3.135
1-Wochen-Bereich:
Value
$2.85
$3.135
52-Wochen-Spanne:
Value
$2.31
$5.31

Savara Inc Stock (SVRA) Company Profile

Name
Firmenname
Savara Inc
Name
Telefon
51285113796
Name
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Name
Mitarbeiter
59
Name
Twitter
@SavaraPharma
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
SVRA's Discussions on Twitter

Vergleichen Sie SVRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SVRA
Savara Inc
3.05 500.64M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Savara Inc Stock (SVRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Eingeleitet Wells Fargo Overweight
2024-11-13 Herabstufung Evercore ISI Outperform → In-line
2024-02-15 Eingeleitet JMP Securities Mkt Outperform
2023-11-07 Eingeleitet Guggenheim Buy
2023-05-16 Hochstufung Jefferies Hold → Buy
2023-03-31 Herabstufung Jefferies Buy → Hold
2021-03-16 Eingeleitet Piper Sandler Overweight
2021-03-15 Eingeleitet Oppenheimer Outperform
2019-06-13 Bestätigt H.C. Wainwright Buy
2019-06-13 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 Herabstufung Ladenburg Thalmann Buy → Neutral
2018-08-13 Fortgesetzt ROTH Capital Neutral
2018-01-03 Eingeleitet Ladenburg Thalmann Buy
2017-09-27 Fortgesetzt ROTH Capital Buy
2017-09-22 Eingeleitet Jefferies Buy
2017-09-11 Eingeleitet JMP Securities Mkt Outperform
Alle ansehen

Savara Inc Aktie (SVRA) Neueste Nachrichten

pulisher
11:16 AM

Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha

11:16 AM
pulisher
Apr 20, 2025

Savara Inc. Announces Equity Awards for New Employees - MSN

Apr 20, 2025
pulisher
Apr 20, 2025

JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World

Apr 20, 2025
pulisher
Apr 15, 2025

Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Savara Announces New Employment Inducement Grant - The Joplin Globe

Apr 11, 2025
pulisher
Apr 11, 2025

Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Apr 10, 2025
pulisher
Apr 07, 2025

Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Savara to present aPAP treatment study at medical congresses - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan

Apr 07, 2025
pulisher
Apr 06, 2025

259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World

Apr 06, 2025
pulisher
Apr 04, 2025

Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN

Apr 04, 2025
pulisher
Apr 03, 2025

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st

Apr 03, 2025
pulisher
Apr 02, 2025

Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com

Apr 01, 2025
pulisher
Apr 01, 2025

Savara director David Ramsay acquires $416,250 in common stock - Investing.com India

Apr 01, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Savara Inc ends sales agreement with Evercore By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Savara Inc ends sales agreement with Evercore - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Savara enters loan and security agreement with Hercules Capital - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News

Mar 27, 2025
pulisher
Mar 27, 2025

Savara Inc. (SVRA) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Savara Advances First-Ever aPAP Treatment with FDA Filing, Reports $196M Cash Position - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India

Mar 27, 2025

Finanzdaten der Savara Inc-Aktie (SVRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):